Navigation Links
Vital funding for children's brain tumor research
Date:3/4/2011

New research into drugs which could prevent the return of persistent brain tumours in children has won vital funding from two major brain tumour charities.

The pioneering work in this historically underfunded area is being carried out at the Children's Brain Tumour Research Centre at The University of Nottingham, one of the centres of excellence in Europe.

The new research has been jointly funded by the Samantha Dickson Brain Tumour Trust and the Joseph Foote Charitable Trust, both charities set up by families who have lost children to the disease.

The scientists will be investigating 'ependymoma', a tumour type from which less than half of the children diagnosed will survive. It's a type that usually affects children, and develops from the cells lining the fluid-filled spaces in the brain called ventricles. Even after surgical removal combined with chemotherapy and radiotherapy, this type of cancer tends to return in a therapy-resistant form in up to half of the cases.

Normal, healthy cells use 'tumour suppressor genes' to help control their growth. But in certain ependymoma cells, some of these genes are de-activated by proteins called 'histone deacetylases', allowing the cells to grow and multiply in an uncontrolled way.

The team is investigating a group of drugs called 'histone deacetylase inhibitors' (HDACi) which are designed to re-activate the body's natural defence mechanisms against brain cancer. Previous work by the group in the lab shows that the HDACi 'Trichostatin A' causes most ependymoma cells to grow more slowly and eventually die. One HDACi is currently being trialled in the treatment of adult patients with another type of brain tumour, 'glioblastoma multiforme'.

Leading the research, Professor Richard Grundy, said: "This is vital funding which will make a real difference to our work. It is hoped that this research will lead to a better understanding of the biology of the cancer cells that return following initial treatment, and of the factors responsible for their resistance to therapy. This could lead to new ways to predict how these tumours will behave, and how ependymoma cells can be targeted and destroyed by new cancer drugs."

Paul Carbury, CEO of the Samantha Dickson Brain Tumour Trust, said: "We are proud to be working with the Joseph Foote Charitable Trust to offer funding that will facilitate this vital research. The fact that this new project was selected through our accredited competitive peer review process shows that it is especially deserving of our support. We're optimistic that it will directly lead to the development of a new and effective treatment that will improve patients' outlooks and could save lives."

Andy Foote of the Joseph Foote Charitable Trust added: "Our organisation was set up to fund research just like this, as it was an ependymoma that led to the tragic loss of our son, Joseph. Both the SDBTT and the JFCT have a strong track record of funding research, including previous work at The University of Nottingham, and it is our constant hope that partnerships such as this will produce results which will give cause for optimism for anyone whose lives are affected by brain cancer."


'/>"/>

Contact: Emma Rayner
emma.rayner@nottingham.ac.uk
44-115-951-5793
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Protein and microRNA block cellular transition vital to metastasis
2. Samples of vital human tumor tissue irradiated with ions for the first time
3. Additional cardiac testing vital for patients with anxiety and depression
4. Sunglasses Rival Lotions as Vital for Safety
5. Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor
6. Researchers develop advanced search tool to help physicians sort and retrieve vital EMR data
7. Get Moving Can Be Vital Advice for Seniors
8. MedTouch Launches Revitalized Website for Sterling Life Insurance Company
9. Vitals.com Recognizes Two RMACT Fertility Doctors as 'Leading On-Time Doctors'
10. Vital functions monitored with wearable and implantable devices
11. Grandparents Play Vital Role for Autistic Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: